| Technical Name | 糖尿病症狀胰臟癌病患精準診斷平台 | ||
|---|---|---|---|
| Project Operator | National Taiwan University Centers of GenomicPrecision Medicine | ||
| Project Host | 周綠蘋 | ||
| Summary | Monitoring PCDM-specific biomarkers, galectin-3S100A9, to serve as a risk assessment of pancreatic cancer on new-onset diabetes patients for early detection of PC. |
||
| Scientific Breakthrough | Pancreatic cancer is a highly regarded cancer type with five-year survival rate of ~5. Most of the patients were diagnosed at the late stage of the disease. The importance of our research is the discovery of two novelspecific PCDM biomarkers, galectin-3S100A9, which make a critical breakthrough toward early diagnosis of pancreatic cancer. |
||
| Industrial Applicability | To develop high sensitivityaccuracy galectin-3S100A9 diagnostic platform for pancreatic cancer early detection in specific new-onset diabetes patients. |
||
| Matching Needs | 天使投資人、策略合作夥伴 |
||
| Keyword | Pancreatic Cancer New-onset Diabetes Biomarker Galectin-3 S100A9 Early Detection Proteomics Precision Diagnostics Detection Kit Rapid Screening Biochip | ||
| Notes | |||
- Contact
- yslee@ntu.edu.tw
other people also saw
